Details of the Drug

General Information of Drug (ID: )

• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw)
  Logarithm of the Partition Coefficient (xlogp)
  Rotatable Bond Count (rotbonds)
  Hydrogen Bond Donor Count (hbonddonor)
  Hydrogen Bond Acceptor Count (hbondacc)
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 129.6 mcg/L [1]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3.26 h [1]
  Bioavailability: The bioavailability of drug is 67-74% [1]
  Clearance: The clearance of drug is 17.7 L/h in women [2]
  Elimination: About 74% of the total dose was excreted in urine and 22% was excreted in feces, mostly in the form of hydroxyl and oxo metabolites of ruxolitinib [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3 hours [2]
  Metabolism: The drug is metabolized via the CYP3A4 [3]
  Vd: The volume of distribution (Vd) of drug is 72 L [2]

References

• [1] Furst DE: Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996 Jun;5 Suppl 1:S11-5.
• [2] FDA Approved Drug Products: JAKAFI (ruxolitinib) tablets, for oral use
• [3] English BA, Dortch M, Ereshefsky L, Jhee S: Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012 Aug;14(4):376-90. doi: 10.1007/s11920-012-0284-9.